Start the conversation
Two big deals.
Two big trading days for a promising biotech.
Shares of our "Liquid Biopsy" play TrovaGene Inc. (Nasdaq: TROV) rocketed as much as 23% today after the tiny biotech announced its second major deal in the last two weeks.
Another deal - announced back on Jan. 21 - ignited a single-day gain of 70%.
This is premium content for Private Briefing subscribers only.